These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23175507)

  • 1. Pre-existing immunity against vaccine vectors--friend or foe?
    Saxena M; Van TTH; Baird FJ; Coloe PJ; Smooker PM
    Microbiology (Reading); 2013 Jan; 159(Pt 1):1-11. PubMed ID: 23175507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
    Betts G; Poyntz H; Stylianou E; Reyes-Sandoval A; Cottingham M; Hill A; McShane H
    PLoS One; 2012; 7(12):e50447. PubMed ID: 23284637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.
    Knuchel MC; Marty RR; Morin TN; Ilter O; Zuniga A; Naim HY
    Hum Vaccin Immunother; 2013 Mar; 9(3):599-606. PubMed ID: 23324399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Vaccines - A Modern Gimmick or a Boon to Vaccinology?
    Manickan E; Karem KL; Rouse BT
    Crit Rev Immunol; 2017; 37(2-6):483-498. PubMed ID: 29773031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviruses as vaccine vectors.
    Tatsis N; Ertl HC
    Mol Ther; 2004 Oct; 10(4):616-29. PubMed ID: 15451446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant viruses as vaccines against viral diseases.
    Souza AP; Haut L; Reyes-Sandoval A; Pinto AR
    Braz J Med Biol Res; 2005 Apr; 38(4):509-22. PubMed ID: 15962176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing poxvirus vectors vaccine immunogenicity.
    García-Arriaza J; Esteban M
    Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New viral vectors for infectious diseases and cancer.
    Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
    Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery.
    Kaulfuß M; Wensing I; Windmann S; Hrycak CP; Bayer W
    Retrovirology; 2017 Feb; 14(1):8. PubMed ID: 28166802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward the development of vectored vaccines in compliance with evolutionary medicine.
    Tang DC; Van Kampen KR
    Expert Rev Vaccines; 2008 May; 7(4):399-402. PubMed ID: 18444885
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
    Jia Q; Bowen R; Dillon BJ; Masleša-Galić S; Chang BT; Kaidi AC; Horwitz MA
    Sci Rep; 2018 May; 8(1):7009. PubMed ID: 29725025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vaccines and the development of new vaccine strategies.
    Nascimento IP; Leite LC
    Braz J Med Biol Res; 2012 Dec; 45(12):1102-11. PubMed ID: 22948379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel viral vectors in infectious diseases.
    Humphreys IR; Sebastian S
    Immunology; 2018 Jan; 153(1):1-9. PubMed ID: 28869761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral vectors as vaccine platforms: from immunogenicity to impact.
    Ewer KJ; Lambe T; Rollier CS; Spencer AJ; Hill AV; Dorrell L
    Curr Opin Immunol; 2016 Aug; 41():47-54. PubMed ID: 27286566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
    Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
    J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models.
    Guo Q; Chan JF; Poon VK; Wu S; Chan CC; Hou L; Yip CC; Ren C; Cai JP; Zhao M; Zhang AJ; Song X; Chan KH; Wang B; Kok KH; Wen Y; Yuen KY; Chen W
    J Infect Dis; 2018 Jul; 218(3):365-377. PubMed ID: 29617816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.
    Barratt-Boyes SM; Soloff AC; Gao W; Nwanegbo E; Liu X; Rajakumar PA; Brown KN; Robbins PD; Murphey-Corb M; Day RD; Gambotto A
    J Gen Virol; 2006 Jan; 87(Pt 1):139-149. PubMed ID: 16361426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.
    Wortmann A; Vöhringer S; Engler T; Corjon S; Schirmbeck R; Reimann J; Kochanek S; Kreppel F
    Mol Ther; 2008 Jan; 16(1):154-62. PubMed ID: 17848961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.